Previous Close | 0.65 |
1-Year Change | -92.48% |
6-Months Change | -86.34% |
3-Months Change | -85.87% |
Moving Avg (50d) | 1.8602 |
Moving Avg (200d) | 4.1658 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 8.51M |
Beta (3-Years) | 0.79 |
Revenue Growth (ttm) | -5.38% |
Net Profit Margin (ttm) | 4.64% |
Return On Assets (ttm) | 2.95% |
EPS (ttm) | 0.91 |
PE Ratio (ttm) | 0.71 |
Dividend Yield | % |
Asset Description: | Eagle Pharmaceuticals, Inc. |
Predicted Direction: | Sell |
Signal Strength: | Sell |
Forecast Date: | 2024-11-04 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
0.665 | 0.685 | 0.698 | 0.717 | 0.75 | 0.782 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.